Exam 3 Flashcards
abnormal clot in vitro, retraction and normal plt count
Glanzmann Thrombasthenia
What is clot retraction
volume of a formed clot is reduced through contraction of cytoskeleton of activated plts within the clot
Deficiency or abnormality of the plt membrane GP IIb/ IIIa complex
Glanzmann Thrombasthenia
Petechiae, purpura, menorrhagia, GI bleeding, hematuria
Glanzmann Thrombasthenia
What levels of GP in Glanzmann thrombasthenia
homo severely decreased to no GP IIb/ IIIa
hetero- 50-60% of normal GP IIb/ IIIa
Lab test in Glantzmann Thrombasthenia
plts normal
lack of aggregation in response to all plt activating agents
diminished plt activity
How is GT treated
normal plt transfusion
What type of platelet disorder is GT
platelet aggregation
platelet disorder where GP Ib/ IX/ V complex is missing from platelet surface
Bernard Soulier Giant platelet syndrome
If there is an inability to bind to VWF, then platelets have an inability to
adhere to exposed subendothelial cells, causes bleeding
In childhood: Ecchymoses, epistaxis, gingival bleeding
Bernard-Soulier Giant platelet syndrome
How is Bernard Soulier treated
cannot be correct by adding plasma
afibrinolytic therapy- treat the mucosal bleeding
What glycoprotein defect is most often the cause of BSS
GP Ib alpha
normal ADP, epi, collagen, arachadonic
no response to ristocetin
What lab results can be expected from BSS
What is the main disorder of plt aggregation
and plt adhesion?
aggregation- Glanzmann Thrombsthenia
adhesion- Bernard Soulier Giant plt
normal plt count
mucocutaneous hemorrhage, hematuria, epistaxis, easy bruising
platelet secretion
What are dense granules
storage site for serotonin, nucelotides, Ca and pyrophosphate
Deficiency associated with albinism
Dense granules
Plt aggregation test shows an aggregation pattern affected by ADP
What deficiency is this
Arachidonic acid …
epi and low dose ADP …..
Collagen …..
dense granules
Arachidonic acid … no response
epi and low dose ADP …..primary wave, no secondary
Collagen ….. decreased
dense granule deficiency that shows defective lysosomal function
Hermansky-Pudlak syndrome
Swiss cheese plts
Hermansky-Pudlak syndrome
Dense granule deficiency that causes giant lysosomal granules
Chediak Higashi syndrome
Dense granule deficiency that causes microthrombocytopenia
Wiskottp-Aldrich Syndrome WAS
Dense granule deficiency that is autosomal recessive and causes an absence of radial bones
Thrombocytopenia with absent Radii syndrome
TAR
What are alpha granules
storage site for proteins produced by the megakaryocyte or present in plasma and taken up by plts
Primary reason for platelets to have a granular appearance
alpha granules
absence of alpha granules
gray platelet syndrome
large plts with a gray appearance
gray plt syndrome
Which part of the platelet is affect in storage pool diseases
dense granules
Deficiency that leads to lifelong mild bleeding disorder,
platelets do not adhere to collagen
collagen receptor deficiencies
What are the 3 ADP receptors
P2X1 - Ca ion influx
P2Y1 Ca mobilization and shape change in response to ADP
P2Y12 macroscopic plt aggregation
No Phospholipid flip
Scott syndrome
no binding of vitamin K dependent factors
platelets always in activated state
Stormorken syndrome
What can case acquired defects of platelet function
drug ingestion
What drug
irreversible acetylates/ inactivates cyclooxygenase
aspirin
What is not affected by aspirin
endothelial cells- produce nitric oxide, a plt inhibitor, making them unaffected by aspirin
drugs that inhibit cyclooxygenase are ____
reversible
How do P2Y12 ADP receptor inhibitors work
plt activation and aggregation are induced by ADP and inhibited
Clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor
P2Y12 ADP receptor inhibitors
How does clopidogrel (plavix) work
needs to be converted to an active drug by a liver enzyme
CYP2C19 gene
clopidogrel plavix
Platelet drug that interferes with fibrinogen, inhibits plt aggregation
GP IIb/ IIIa receptor inhibitor
Drug used with patients under percutaneous coronary intervention
GP IIb/ IIIa receptor inhibitors
Drug that inhibits thrombin by blocking binding site on PAR-1
PAR-1 antagonist